Russian pharmaceutical company Zavod Medsintez and its Pakistani partner Genetics Pharmaceuticals Private Limited plan to invest nearly $80 million in Pakistan’s pharmaceutical sector to launch local insulin production, sources said on Monday.
The investment will be carried out in two phases, including the establishment of an aseptic filling plant and a full-scale insulin manufacturing facility.
Under the first phase, the companies will invest around $20 million to build an aseptic filling plant for insulin and related products. The facility, which will handle bulk imports and local filling operations, is expected to be completed by December 2028.
The second phase involves a $60 million investment in an Active Pharmaceutical Ingredient (API) production plant.
The project will include technology transfer and the development of biotechnology products, including insulin manufacturing from API purification to final packaging through C Biotech. This phase is expected to be completed by December 2031.
Meanwhile, the Drug Regulatory Authority of Pakistan (DRAP) has allowed the Russian manufacturer and its local partner to market Rosinsulin R, Rosinsulin C, and Rosinsulin M 30/70 insulin products in Pakistan.
Sources said DRAP will closely monitor the progress of the project and require detailed stage-wise investment timelines from both companies.
The development comes amid growing economic cooperation between Pakistan and Russia. Earlier, Russia approved imports of Pakistani fish and seafood, allowing 16 Pakistani companies to export seafood products to the Russian market.
Federal Minister for Maritime Affairs Muhammad Junaid Anwar Chaudhry described the move as a historic achievement, saying it could significantly increase Pakistan’s seafood exports in the coming years.
📢 For the latest General & Pakistan news and analysis join ProPakistani's WhatsApp Group now!
Follow ProPakistani on Google News & scroll through your favourite content faster!
Shares
